Coco Danilo, Leanza Silvana
Department of General, Robotic, Oncologic Surgery, Giglio Hospital Foundation, Cefalù, Italy.
J Robot Surg. 2025 Aug 13;19(1):481. doi: 10.1007/s11701-025-02602-z.
Anastomotic leakage (AL) remains a critical complication following left-sided colectomy, with severe leaks (Grade C) significantly increasing mortality and healthcare costs. Robotic surgery offers technical advantages, but large-scale comparative data on AL severity, survival, and cost-effectiveness are limited. Using a national registry (2014-2025), 2916 robotic and laparoscopic left colectomy cases were 1:1 propensity-matched for age, sex, BMI, ASA class, tumor location, and operative year. Outcomes included AL severity (Colorectal Leakage Score), conversion rates, lymph node yield, survival, and cost-effectiveness. Robotic procedures increased from 8% (2014) to 35% (2025; p < 0.001). Compared to laparoscopy, robotics reduced conversion rates by 58% (4.2% vs. 9.8%; p < 0.001) and AL by 42% (4.5% vs. 7.8%), with a 51% reduction in Grade C leaks (1.2% vs. 2.1%). Robotic cases had higher lymph node yields (28 vs. 24 nodes; p < 0.001), wider margins (8.5 vs. 6.3 mm; p = 0.002), and improved 5-year survival (78.2% vs. 74.5%). Despite 18% higher upfront costs ($14,200 vs. $12,050), robotics saved $3850 per patient in complication-related costs, yielding an ICER of $28,500/QALY. Robotic left colectomy reduces severe AL, improves oncologic outcomes, and is cost-effective. The benefits are most pronounced in advanced-stage and technically challenging cases, supporting selective adoption in universal healthcare systems.
吻合口漏(AL)仍是左半结肠切除术后的一种严重并发症,严重漏(C级)会显著增加死亡率和医疗成本。机器人手术具有技术优势,但关于AL严重程度、生存率和成本效益的大规模比较数据有限。利用一个国家登记处(2014 - 2025年)的数据,对2916例机器人辅助和腹腔镜左半结肠切除术病例按年龄、性别、体重指数、美国麻醉医师协会(ASA)分级、肿瘤位置和手术年份进行1:1倾向匹配。结果包括AL严重程度(结直肠漏评分)、转化率、淋巴结收获量、生存率和成本效益。机器人手术的比例从2014年的8%增至2025年的35%(p < 0.001)。与腹腔镜手术相比,机器人手术使转化率降低了58%(4.2%对9.8%;p < 0.001),使AL降低了42%(4.5%对7.8%),C级漏减少了51%(1.2%对2.1%)。机器人手术病例的淋巴结收获量更高(28个对24个淋巴结;p < 0.001),切缘更宽(8.5毫米对6.3毫米;p = 0.002),5年生存率更高(78.2%对74.5%)。尽管机器人手术的前期成本高出18%(14,200美元对12,050美元),但在并发症相关成本方面,机器人手术为每位患者节省了3850美元,成本效果比为28,500美元/质量调整生命年。机器人辅助左半结肠切除术可减少严重AL,改善肿瘤学结局,且具有成本效益。这些益处在晚期和技术难度大的病例中最为明显,支持在全民医疗体系中选择性采用。